echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Anesthesia Topics > 2019 Annual Meeting of the American Academy of Neurology: Teva will announce the long-term efficacy and safety data of Fremanezumab

    2019 Annual Meeting of the American Academy of Neurology: Teva will announce the long-term efficacy and safety data of Fremanezumab

    • Last Update: 2021-12-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Teva Pharmaceuticals recently announced that it will announce the results of a long-term analysis of the effectiveness and safety of Fremanezumab at the 71st Annual Meeting of the American Academy of Neurology ( AAN ) .


    Teva Pharmaceuticals recently announced that it will announce the results of a long-term analysis of the effectiveness and safety of Fremanezumab at the 71st Annual Meeting of the American Academy of Neurology ( AAN ) .


    Fremanezumab is a fully humanized monoclonal antibody directed against calcitonin gene-related peptide ( CGRP ) α and β



    Original source: Original source: Original source:

    http://#axzz5mwpWeWX8

    http://#axzz5mwpWeWX8 http://#axzz5mwpWeWX8 http://#axzz5mwpWeWX8http://www .


    This article is Metz Medicine ( MedSci ) original finishing compiler, Reprinted with authorization ! This article is Metz Medicine ( This article is Metz Medicine (This article is Metz Medicine ( MedSci MedSciMedSci ) original finishing compiler, Reprinted with authorization ) original finishing compiler, reprinted with authorization) original finishing compiler, reprinted with authorization ! !!

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.